Positive selection (discover binders)
Phage library
Target antigen
Specific binders
- Multiple panning rounds progressively improve specificity
- Enrichment trends support strategy assessment
- Retain diverse positive clones for sequencing
Phage display antibody discovery
Phage display antibody discovery service
Evidence retained from selection strategy through candidate sequences
Using phage-displayed antibody libraries, we combine antigen presentation, positive enrichment, counter-selection and progressive stringency to identify candidates with the intended binding profile.
Projects can extend to sequence clustering, monoclonal verification, affinity and functional assessment, creating a traceable basis for antibody engineering and production.
Service overview
Service overview
A selection framework combining positive enrichment and counter-selection according to antigen format, background risk and downstream use.
Counter-selection (remove nonspecific binding)
Carrier / homologue
Target-specific clones retained
Carrier / tag binders removed
- Remove carrier or homologue background binders
- Reduce false positives and improve specificity
- Improve quality of candidates entering validation
Service advantages
An evidence-led antibody selection system.
Application-led design
Antigen format, epitope intent, cross-reactivity boundaries and downstream use are aligned before selection.
Positive and counter-selection
Target enrichment is combined with counter-selection against tags, carriers, homologues or non-target cells.
Antibody fragment–sequence linkage
Selected antibody fragments remain linked to their sequences for deduplication, clustering and representative candidate selection.
Layered validation
Binding, specificity and function can be assessed across complementary assay platforms.
Format conversion support
Expression and purification can be connected across antibody formats for downstream validation.
Traceable decision points
Raw data and analysis are retained at each decision point for review and downstream development.
Service workflow
Five steps with clear execution records and stage outputs.
PHASE I · STRATEGY
PHASE II · PANNING
PHASE III · DELIVERY
01
Project assessment
EXECUTION
Align antigen, epitope intent and application; identify tag, carrier and homologue risks.
OUTPUT
Assessment record; selection framework
02
Antigen and library setup
EXECUTION
Choose solid, solution or cell-based presentation; prepare controls and counter-selection materials.
OUTPUT
Presentation plan; experimental design
03
Panning and enrichment
EXECUTION
Incubate, wash, elute and amplify; adjust stringency and monitor enrichment.
OUTPUT
Round records; enrichment trends
04
Monoclonal screening
EXECUTION
Test monoclonal binding against controls; sequence, deduplicate and cluster families.
OUTPUT
Positive clone list; sequence clusters
05
Candidate confirmation
EXECUTION
Retest and rank candidates; compile raw data, conclusions and next steps.
OUTPUT
Candidate shortlist; data package and report
Frequently asked questions
What is phage display antibody selection?+
Antibody phenotype and encoding sequence are linked on the same phage particle, enabling iterative binding, washing, elution and amplification.
How many rounds are typical?+
Multiple rounds are common, but enrichment, background and clone diversity determine whether the strategy continues or changes.
Which antigen formats can be used?+
Purified proteins, domains, peptides, cells or other agreed formats may be used depending on conformational and validation needs.
How is nonspecific binding reduced?+
Blocking, pre-adsorption, counter-selection, competitive elution and progressively stringent washing can be combined with controls.
Are CDR annotations included?+
Scope is confirmed at project start. Sequence files and clustering can be supplied, while annotation and reformatting can be planned separately.
Can candidates proceed to expression and validation?+
Yes. Candidates can proceed to production, affinity, competition, cross-reactivity and goal-specific functional assays.